Barinthus Biotherapeutics (BRNS) Deferred Taxes (2021 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Deferred Taxes came in at -$16000.0 in Q1 2026, up 27.27% YoY from -$12571.4 in Q1 2025, and up 71.93% on a QoQ basis from -$57000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Deferred Taxes (2021 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 6 years of Deferred Taxes data on file, last reported at -$16000.0 in Q1 2026.
- Quarterly Deferred Taxes rose 27.27% year-over-year to -$16000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$169000.0 (down 482.76% YoY) and the FY2025 annual result came in at -$175000.0, down 297.73% from the prior year.
- Deferred Taxes improved to -$16000.0 in Q1 2026, from -$57000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $3000.0 in Q4 2024 to a low of -$1.9 million in Q4 2022.
- A 5-year average of -$449823.5 and a median of -$71000.0 in 2025 frame the typical range for Deferred Taxes.
- Annual changes were most pronounced in 2022 — Deferred Taxes slumped 12971.43% — and 2024, when it jumped 100.37%.
- Tracing BRNS's Deferred Taxes over 5 years: stood at -$1.9 million in 2022, then soared by 57.55% to -$821000.0 in 2023, then jumped by 100.37% to $3000.0 in 2024, then sank by 2000.0% to -$57000.0 in 2025, then soared by 71.93% to -$16000.0 in 2026.
- The last three Deferred Taxes figures came in at -$16000.0 (Q1 2026), -$57000.0 (Q4 2025), and -$71000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.66 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | -23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23,000.00 |
| Mar 31, 2026 | -16,000.00 |
| Dec 31, 2025 | -57,000.00 |
| Sep 30, 2025 | -71,000.00 |
| Jun 30, 2025 | -25,000.00 |
| Mar 31, 2025 | -22,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | -3,000.00 |
| Jun 30, 2024 | -7,000.00 |
| Mar 31, 2024 | -37,000.00 |
| Dec 31, 2023 | -821,000.00 |
| Sep 30, 2023 | -602,000.00 |
| Jun 30, 2023 | -1.14 Mn |
| Mar 31, 2023 | -516,000.00 |
| Dec 31, 2022 | -1.93 Mn |
| Sep 30, 2022 | -625,000.00 |
| Jun 30, 2022 | -915,000.00 |
| Mar 31, 2022 | -863,000.00 |
| Dec 31, 2021 | -57,000.00 |
| Sep 30, 2021 | -30,000.00 |